CRT Capital Cuts Valeant Pharmaceuticals to Buy (VRX)

By admin | 7 years ago

Valeant Pharmaceuticals (NYSE: VRX) was downgraded by analysts at CRT Capital to a “buy” rating in a research report issued to clients and investors on Thursday.

Separately, analysts at RBC Capital (NYSE: RY) raised their price target on shares of Valeant Pharmaceuticals from $56.00 to $58.00 in a research note to investors on Tuesday, February 28th. They now have an “outperform” rating on the stock.

Shares of Valeant Pharmaceuticals traded up 0.04% during mid-day trading on Thursday, hitting $51.26. Valeant Pharmaceuticals has a one year low of $32.05 and a one year high of $59.94. The company has a market cap of $15.715 billion and a P/E ratio of 104.57.

The company last announced its quarterly results on Thursday, May 3rd. It reported $0.99 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.96 EPS by $0.03. The company’s quarterly revenue was up 51.5% on a year-over-year basis. Analysts expect that Valeant Pharmaceuticals will post $0.00 EPS next quarter.

Valeant Pharmaceuticals International Inc., formerly Biovail Corporation, is a specialty pharmaceutical company.

About the author